Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label previous answer version answering member constituency answering member printed answering member label
tabling member	label

Search

872272

registered interest
date	26/03/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Acute Lymphoblastic Leukaemia: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what assessment he has made of the availability of treatments for patients diagnosed with Refractory B-cell Acute Lymphoblastic Leukaemia.
tabling member constituency	Crawley
tabling member printed	Henry Smith
uin	134186
answer	answer is ministerial correction date of answer 03/04/2018 answer text <p>The following treatments are routinely available, having undergone Technical Appraisals by the National Institute for Health and Care Excellence (NICE). They were previously accessible through the Cancer Drugs Fund.</p><p> </p><p>- Blinatumomab for relapsed refractory (r/r) Philadelphia negative acute lymphoblastic leukaemia (ALL); and</p><p>- Ponatinib for Philadelphia positive ALL in patients in whom imatinib is not clinically appropriate (which might cover some r/r).</p><p> </p><p>The following treatments are currently under consideration by NICE:</p><p> </p><p>- CAR-T (Tisagenlecleucel-T and also Axicabtagene ciloleucel) for previously treated B-cell ALL in people aged 3 to 21 at initial diagnosis;</p><p>- Inotuzumab ozogamicin for treating r/r ALL; and</p><p>- Blinatumomab in other extended indications in ALL.</p><p> </p><p>Finally, the following treatments are currently accessible through the Cancer Drugs Fund.</p><p> </p><p>- Clofarabine for treating ALL in children after two therapies; and</p><p>- Nelarabine for treating ALL after two therapies.</p><p> </p><p>Information on the number and proportion of patients with refractory B-cell Acute Lymphoblastic Leukaemia who have been unable to access treatments for that condition is not held centrally.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 134187 question first answered 03/04/2018 13:25:08 answering member 4067 label Biography information for Steve Brine
tabling member	3960 label Biography information for Henry Smith

872274

registered interest
date	26/03/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Cancer and Rare Diseases: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what recent assessment he has made of the effectiveness of NICE appraisals for new treatments for rare (a) diseases and (b) cancers.
tabling member constituency	Crawley
tabling member printed	Henry Smith
uin	134188
answer	answer is ministerial correction date of answer 03/04/2018 answer text <p>Most new drugs and significant licence indications are assessed by the National Institute for Health and Care Excellence (NICE) through its technology appraisal programme, through which NICE has been able to recommend a significant number of drugs for the treatment of rare cancers and other diseases for routine use on the National Health Service. NICE also operates a separate Highly Specialised Technology evaluation programme for the evaluation of a very small number of treatments for very rare diseases.</p><p>The methods and processes NICE uses in the development of its guidance are internationally respected, have been developed through extensive engagement with a full range of stakeholders, including the Department, and are regularly reviewed to ensure that they remain fit for purpose.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 03/04/2018 13:25:57 answering member 4067 label Biography information for Steve Brine
tabling member	3960 label Biography information for Henry Smith

872275

registered interest
date	26/03/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what discussions he has had with (a) NHS England and (b) NICE on the development of (a) multi-indication pricing, (b) outcomes-based pricing and (c) annuity deals for new treatments.
tabling member constituency	Crawley
tabling member printed	Henry Smith
uin	134189
answer	answer is ministerial correction date of answer 29/03/2018 answer text <p>The Department has regular and ongoing dialogue with NHS England and the National Institute for Health and Care Excellence on matters related to medicines pricing and patient access to new treatments. We will consider all relevant issues in upcoming discussions with the pharmaceutical industry on medicines pricing arrangements for 2019 onwards to succeed the current Pharmaceutical Price Regulation Scheme.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 29/03/2018 14:02:10 answering member 4067 label Biography information for Steve Brine
tabling member	3960 label Biography information for Henry Smith

872373

registered interest
date	26/03/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Cancer Drugs Fund
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what drugs have been funded through the Cancer Drugs Fund this year; and how much funding remains in that Fund.
tabling member constituency	Crawley
tabling member printed	Henry Smith
uin	134287
answer	answer is ministerial correction date of answer 29/03/2018 answer text <p>Since April 2017, there are currently 27 drugs in 42 indications that are funded by the Cancer Drugs Fund (CDF). A full list of current and previous CDF drugs can be viewed at the following link:</p><p> </p><p><a href="https://www.england.nhs.uk/cancer/cdf/cancer-drugs-fund-list/" target="_blank">https://www.england.nhs.uk/cancer/cdf/cancer-drugs-fund-list/</a></p><p> </p><p>The latest published spend for the first six months of 2017/18 implies a circa £76 million of unused funding for that period against the CDF. The quarterly activity report is a snapshot of CDF spend at a point in time and the spend figure will increase as more drugs are added to the fund. The link to the report can be found here:</p><p> </p><p><a href="https://www.england.nhs.uk/wp-content/uploads/2018/01/cdf-activity-update-Q2-2017-18.pdf" target="_blank">https://www.england.nhs.uk/wp-content/uploads/2018/01/cdf-activity-update-Q2-2017-18.pdf</a></p> answering member constituency Winchester answering member printed Steve Brine question first answered 29/03/2018 13:51:19 answering member 4067 label Biography information for Steve Brine
tabling member	3960 label Biography information for Henry Smith

872376

registered interest
date	26/03/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Cancer: Nurses
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether every patient diagnosed with cancer receives support from a clinical nurse specialist; and if he will make a statement.
tabling member constituency	Crawley
tabling member printed	Henry Smith
uin	134290
answer	answer is ministerial correction date of answer 29/03/2018 answer text <p>The Cancer Patient Experience Survey 2016 results show that 90% of respondents said that they were given the name of a clinical nurse specialist who would support them through their treatment. NHS England is working alongside Health Education England to expand the number of Clinical Nurse Specialists (CNS) and develop clear CNS competencies and routes into training. This will ensure every cancer patient has access to a CNS or other support worker by 2021.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 29/03/2018 13:56:27 answering member 4067 label Biography information for Steve Brine
tabling member	3960 label Biography information for Henry Smith

872380

registered interest
date	26/03/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Blood Cancer
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 19 March 2018 to Question 132100, on Haematological Cancer, whether he or NHS England plan to publish information on the work of multidisciplinary diagnostic centres before December 2018.
tabling member constituency	Crawley
tabling member printed	Henry Smith
uin	134294
answer	answer is ministerial correction date of answer 29/03/2018 answer text <p>The 10 multidisciplinary diagnostic centres or ‘rapid assessment and diagnostic centres’ have been described in the Progress Report on the cancer strategy published by NHS England in October 2017 at the following link:</p><p> </p><p><a href="https://www.england.nhs.uk/wp-content/uploads/2017/10/national-cancer-transformation-programme-2016-17-progress.pdf" target="_blank">https://www.england.nhs.uk/wp-content/uploads/2017/10/national-cancer-transformation-programme-2016-17-progress.pdf</a></p><p> </p><p>The evaluation of the centres is being undertaken by the Accelerate, Co-ordinate, Evaluate Partnership, which will publish its final report in December 2018.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 29/03/2018 13:55:02 answering member 4067 label Biography information for Steve Brine
tabling member	3960 label Biography information for Henry Smith

870191

registered interest
date	23/03/2018
answering body	Department for International Trade
answering dept id	202
answering dept short name	International Trade
answering dept sort name	International Trade
hansard heading	Developing Countries: Trade Agreements
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for International Trade, what assessment he has made of the potential effect of UK trade agreements with developing countries on the economies of those countries after the UK leaves the EU.
tabling member constituency	Crawley
tabling member printed	Henry Smith
uin	134061
answer	answer is ministerial correction date of answer 28/03/2018 answer text <p>Britain is an international leader on development, and the Department for International Trade is working with Department for International Development to ensure global prosperity is at the heart of our future trade policy.</p><p>We are committed to ensuring developing countries can use trade as an engine of poverty reduction, and trade agreements play an important role in this.</p><p>In 2016, the UK's total bilateral trade with countries that receive preferential access through unilateral preferences or Economic Partnership Agreements was £58bn.</p><p>Our first priority is to deliver continuity in our trading arrangements on leaving the EU.</p><p>In the future, the Government will also explore options to expand our relationships with developing countries.</p> answering member constituency Chelsea and Fulham answering member printed Greg Hands question first answered 28/03/2018 15:59:16 answering member 1526 label Biography information for Greg Hands
tabling member	3960 label Biography information for Henry Smith

861988

registered interest
date	14/03/2018
answering body	Department for Education
answering dept id	60
answering dept short name	Education
answering dept sort name	Education
hansard heading	STEM Subjects
house id	1
legislature	25259 pref label House of Commons
question text	What steps his Department has taken to increase the take-up of STEM subjects.
tabling member constituency	Crawley
tabling member printed	Henry Smith
uin	904441
answer	answer is ministerial correction date of answer 20/03/2018 answer text <p>The Government is committed to tackling our shortage of STEM skills so we can grow the workforce we need for a dynamic economy. We are doing this by investing in programmes to increase the take-up of maths, by incentivising schools using the recently launched advanced maths premium and supporting better teaching of maths, physics and computing in schools, including a new £84 million programme to improve computing teaching.</p><p> </p><p>To improve the development of technical STEM skills, the Government is introducing T levels, which will be developed with employers, and provide progression opportunities into skilled work or higher level study, including degrees.</p> answering member constituency Bognor Regis and Littlehampton answering member printed Nick Gibb question first answered 20/03/2018 17:26:17 answering member 111 label Biography information for Nick Gibb previous answer version 48392 answering member constituency Bognor Regis and Littlehampton answering member printed Nick Gibb answering member 111 label Biography information for Nick Gibb
tabling member	3960 label Biography information for Henry Smith

860743

registered interest
date	12/03/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Blood Cancer
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care what proportion of patients referred to a multidisciplinary diagnostic centre have been (a) suspected of having blood cancer and (b) diagnosed with blood cancer; and if he will make a statement.
tabling member constituency	Crawley
tabling member printed	Henry Smith
uin	132100
answer	answer is ministerial correction date of answer 19/03/2018 answer text <p>An evaluation is currently being prepared on the work of the multi-disciplinary diagnostic centres, which will include further information on blood cancer patient referral and diagnosis numbers. A final report will be published in December 2018.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 19/03/2018 15:32:36 answering member 4067 label Biography information for Steve Brine
tabling member	3960 label Biography information for Henry Smith

857763

registered interest
date	08/03/2018
answering body	Attorney General
answering dept id	88
answering dept short name	Attorney General
answering dept sort name	Attorney General
hansard heading	Offences against Children: Prosecutions
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Attorney General, what steps the CPS is taking to strengthen (a) cross-agency and (b) international joint working in child abuse cases.
tabling member constituency	Crawley
tabling member printed	Henry Smith
uin	131664
answer	answer is ministerial correction date of answer 21/03/2018 answer text <p>The use of technology means that there are more cases of child abuse that have an international element. Recent successful prosecutions in this field have seen early engagement between the CPS and the police, followed by close collaboration with our overseas prosecutors and international organisations, particularly the National Crime Agency.</p><p> </p><p>Cases of online abuse have highlighted the importance of using expert evidence to demonstrate the true impact on victims, which then has a direct impact on sentence.</p> answering member constituency South Swindon answering member printed Robert Buckland question first answered 21/03/2018 09:19:22 answering member 4106 label Biography information for Sir Robert Buckland
tabling member	3960 label Biography information for Henry Smith